Impurity Control — ICH M7 / FDA & EMA Guidance

Nitrosamine Impurity Risk Assessment: A Complete Guide

A practical framework for assessing, calculating limits for, and controlling nitrosamine impurities — one of the most active and fast-evolving areas in pharmaceutical quality right now.

Why Nitrosamines Became a Global Priority

Since NDMA was first detected in valsartan-containing products in 2018, nitrosamines have driven waves of recalls, testing mandates, and new guidance across FDA, EMA, MHRA, Health Canada, and PMDA. Nitrosamines belong to ICH M7's "cohort of concern" — a small group of structural classes treated as presumed mutagenic carcinogens even without full compound-specific data, because of how potent some members of the class have proven to be.

Marketing authorization holders are now expected to proactively risk-assess every drug substance and product for nitrosamine formation potential — not just react after a problem is found.

📕

Genotoxic Impurities: Strategies for Identification and Control

Andrew Teasdale (ed.) — the foundational reference on the Threshold of Toxicological Concern (TTC) framework that underpins nitrosamine acceptable intake limits.

As an Amazon Associate I earn from qualifying purchases.

Where Nitrosamines Come From

Source	Mechanism
Synthetic route	Secondary/tertiary amines reacting with nitrosating agents (e.g., nitrite-containing reagents) during API synthesis
Raw materials/reagents	Nitrite contamination in excipients, solvents, or starting materials
Nitrosamine Drug Substance-Related Impurities (NDSRIs)	Nitrosation of the API's own amine functional groups, structurally related to the drug substance itself
Packaging/storage	Interaction with nitrocellulose-based blister packaging or nitrite-containing excipients over shelf life

The Risk Assessment Workflow

Step	Focus
1. Hazard identification	Review synthetic route, raw materials, and API structure for nitrosamine formation potential
2. Risk evaluation	Assess likelihood of formation, considering process chemistry and known root causes from prior industry cases
3. Confirmatory testing	Where risk is identified, perform sensitive analytical testing (typically LC-MS/MS or GC-MS) to confirm presence/absence
4. Limit-setting	If detected, establish an Acceptable Intake (AI) and derive a specification limit
5. Control & mitigation	Adjust synthetic route, raw material specifications, or formulation to eliminate or minimize the risk

This is fundamentally a quality risk management exercise — many organizations run it as a structured FMEA, scoring severity, occurrence, and detection for each potential nitrosamine formation pathway.

🔗 Related tool: FMEA Risk Priority Number (RPN) Calculator 🔗 Related tool: Confidence/Reliability Sample Size Calculator

Interactive Tool: AI-Based Specification Limit Calculator

Once a compound-specific or category-based Acceptable Intake (AI) is established (via toxicological assessment or the Carcinogenic Potency Categorization Approach), it is converted into a practical specification limit for the drug product.

Specification Limit (ppm) = Acceptable Intake (µg/day) / Maximum Daily Dose (g/day)

Acceptable Intake, AI (µg/day)

From compound-specific toxicology or CPCA categorization

Maximum Daily Dose (g/day)

Specification Limit

—

Equivalent per Max Dose

—

This calculator applies the standard AI-to-ppm conversion formula for educational purposes only. The correct AI value for a specific nitrosamine must come from current FDA/EMA guidance, a compound-specific toxicological assessment, or an approved CPCA categorization — these values are periodically revised as new data emerges, so always verify against the latest published guidance before using a result for specification-setting.

Specimen Quality Form

A starting template for documenting a nitrosamine hazard screening — fill it in below to see the layout, then transcribe into your controlled document system.

Specimen — Nitrosamine Hazard Screening Record

Drug Substance / Product

Assessment Date

Synthetic Route Summary / Amine-Containing Intermediates

Raw Material / Excipient Nitrite Risk Review

Risk Outcome (Low / Medium / High)

Confirmatory Testing Required? (Y/N)

Assessed By / Date

QA Approval / Date

Common Pitfalls

Pitfall	Fix
Treating this as a one-time assessment	Reassess whenever the synthetic route, raw material suppliers, or formulation changes
Using outdated AI values	Always check the current FDA/EMA published limits — these are revised as new toxicology data emerges
Only testing the API, not the drug product	NDSRIs can form during drug product manufacture or storage — assess both
Underestimating detection method sensitivity needs	Nitrosamine limits are often in the low ppm or even ppb range — confirm your analytical method's LOD/LOQ is adequate

📘

Quality Risk Management in the FDA-Regulated Industry, 2nd Ed.

José Rodríguez-Pérez — the ICH Q9 risk assessment methodology (including FMEA) that structures a defensible nitrosamine hazard screening program.

As an Amazon Associate I earn from qualifying purchases.

This guide is an educational overview. Nitrosamine risk assessment and limit-setting must follow the current FDA/EMA/ICH guidance in effect at the time of assessment, which has been revised multiple times since 2018 — always confirm you are working from the latest published version.